Simplifying Global Compliance
FDAnews Device Daily Bulletin
Biopsy Sciences Gets 483 for Lax CAPA, Supplier Quality Qualms
March 12, 2012
Corrective and preventive action (CAPA) procedures at Biopsy Sciences’ Clearwater, Fla., facility do not ensure analysis of all quality data sources to identify “recurring” quality problems with its HydroMARK breast biopsy site marker and other devices, an FDA Form 483 states. FDA investigators also note in the Sept. 15, 2011, form that when Biopsy Sciences receives a complaint, CAPAs are not always taken to conduct a full investigation to determine root cause.
The GMP Letter
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing